Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Avenue Therapeutics Inc. (ATXI:NASDAQ), powered by AI.
Avenue Therapeutics Inc. is currently trading at $0.20. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Avenue Therapeutics Inc. on Alpha Lenz.
Avenue Therapeutics Inc.'s P/E ratio is -0.0.
“Avenue Therapeutics Inc. trades at a P/E of -0.0 (undervalued) with modest ROE of -532.2%.”
Ask for details →Avenue Therapeutics Inc. is a biopharmaceutical company engaged in the development and commercialization of novel therapies for the treatment of pain. The company's primary focus lies in creating solutions for post-operative pain relief through innovative pharmaceutical products. Avenue Therapeutics specializes in leveraging opioid analgesic drugs, aiming to improve patient outcomes in controlled medical settings. Its operations primarily intersect the healthcare and pharmaceutical industries, catering to medical institutions, healthcare providers, and patients requiring effective pain management solutions. With its commitment to addressing unmet medical needs, Avenue Therapeutics plays a critical role in enhancing pain treatment regimens and expanding therapeutic options available to healthcare professionals, contributing to advancements in patient care and wellbeing within the medical community.
“Avenue Therapeutics Inc. trades at a P/E of -0.0 (undervalued) with modest ROE of -532.2%.”
Ask for details →Avenue Therapeutics Inc. (ticker: ATXI) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 2 employees. Market cap is $263,186.
The current price is $0.203 with a P/E ratio of -0.02x and P/B of 0.09x.
ROE is -532.18%.